Benign Prostatic Hyperplasia Market Analysis, Size, Share & Growth Forecast 2026–2034

Tamsulosin Alpha-1A Prostate-Selective Antagonism 4 to 6-Point IPSS Improvement and Qmax Improvement Without the Blood Pressure Reduction of Non-Selective Alpha-1 Blockers Has Established the Prostate-Selective Mechanism as the Preferred Alpha Blocker for BPH LUTS.Generic tamsulosin from Boehringer Ingelheim, Astellas Pharma, and over 20 generic manufacturers achieves approximately 80% urinary symptom relief in men with moderate BPH at annual costs below USD 50, generating the largest urology prescription volume in primary care where general practitioners manage the majority of BPH patients without specialist referral. The combination of tamsulosin plus dutasteride Jalyn demonstrated superior symptom reduction and reduced acute urinary retention risk versus either monotherapy in CombAT, and the fixed combination eliminates the separate prescription management burden that reduces combination adherence when the agents are prescribed separately. Tamsulosin biosimilar competition following generic entry has compressed brand-to-generic price ratios to under 5-fold in most markets, and the commodity generic BPH market is distinguished from specialty branded therapy only by the small proportion of patients requiring minimally invasive procedural escalation when pharmacotherapy provides inadequate symptom control.

CombAT Trial Dutasteride Plus Tamsulosin Combination 66 Percent Lower BPH Progression Rate and Superior 4-Year IPSS Improvement Versus Tamsulosin Monotherapy Has Established the Complementary Immediate Smooth Muscle Relaxation Plus Long-Term Volume Reduction Strategy for the Large Prostate Patient.Teleflex's UroLift demonstrated 64% improvement in IPSS versus 11% for sham at 3 months in L.I.F.T. with significantly lower rates of de-novo ejaculatory dysfunction compared to TURP, addressing the substantial population of sexually active men with moderate BPH who decline medication escalation due to ejaculatory adverse effects. The office-based procedure under local anaesthesia and the absence of general anaesthesia requirements distinguishes UroLift from TURP and laser ablation procedures that require operating room time and anaesthesia support, enabling performance in urology clinic settings that dramatically reduces procedure cost and patient scheduling burden. Real-world registry data shows 76% of patients continuing to report UroLift benefit at 5 years without surgical re-intervention, comparable to the long-term durability of medication but without ongoing daily medication requirements that affect a substantial proportion of BPH patients who eventually discontinue pharmacotherapy due to side effects or preference.

UroLift Prostatic Urethral Lift LIFT and BPH6 11-Point IPSS Improvement With Preserved Ejaculatory Function From Mechanical Lobe Retraction Without Thermal Energy Has Established the Sexual-Function-Preserving Office Procedure for the BPH Patient Who Prioritises Ejaculatory Preservation.Boston Scientific's Rezum delivered via transurethral steam convection achieved 44.3% IPSS reduction versus 11.9% for sham at 3 months in the pivotal trial, with 94.4% ejaculatory function preservation versus 57% following TURP that has driven rapid adoption among patients and urologists seeking effective symptom relief without retrograde ejaculation. The 9-minute outpatient procedure under local anaesthesia with a single treatment achieving durable symptom relief at 5 years provides a distinct value proposition over UroLift's mechanical implant approach and over TURP's hospitalisation requirement, and comparative effectiveness data from WATER II demonstrates that Rezum's tissue ablation mechanism achieves larger absolute IPSS reduction than UroLift in prostates above 80 mL. Medicare's 2020 transitional pass-through payment for Rezum enabled outpatient urology practice adoption that had been limited by inadequate procedural reimbursement under existing codes, and the expanded reimbursement environment has accelerated diffusion from early-adopting academic centres to community urology practices.

For related market intelligence, see the Erectile Dysfunction Market.